Briefly, the findings of the current exploration show that AIM2 contributes significantly to the development and proliferation of GC cells through a mechanism dependent upon MAPK signaling, highlighting AIM2 as a viable biomarker and potential therapeutic target in GC. The gene discussed is AIM2; the disease is gastric cancer.